- $1.99bn
- $1.88bn
- $237.22m
- 79
- 12
- 56
- 47
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 85.96 | ||
| PEG Ratio (f) | 1.8 | ||
| EPS Growth (f) | 91.26% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.82 | ||
| Price to Tang. Book | 6.97 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 8.4 | ||
| EV to EBITDA | 187.21 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 1.18% | ||
| Return on Equity | 4% | ||
| Operating Margin | 1.9% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 124.18 | 156.18 | 164.37 | 197.52 | 237.22 | 286.61 | 356.56 | 15.02% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -65.85 | n/a | n/a | n/a | n/a | +64.58 | +126.06 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full-thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adult and pediatric patients with deep partial thickness and/or full-thickness thermal burns.
Directors
- Robert Zerbe NEC (70)
- Dominick Colangelo PRE (57)
- Joseph Mara CFO (45)
- Michael Halpin COO (59)
- Sean Flynn VPR
- Jonathan Hopper OTH (58)
- Steven Gilman IND (68)
- Heidi Hagen IND (52)
- Kevin Mclaughlin IND (64)
- Alan Rubino IND (66)
- Paul Wotton IND (60)
- Lisa Wright IND
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 24th, 1989
- Public Since
- February 4th, 1997
- No. of Shareholders
- 166
- No. of Employees
- 357
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 50,135,864
- Address
- 64 Sidney St, CAMBRIDGE, 02139
- Web
- https://vcel.com/
- Phone
- +1 7349305555
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for VCEL
Vericel Corp Annual Shareholders Meeting
Q1 2025 Vericel Corp Earnings Call
Q1 2025 Vericel Corp Earnings Release
Q2 2025 Vericel Corp Earnings Release
Similar to VCEL
111
NASDAQ Global Market
ADMA Biologics
NASDAQ Global Market
ANI Pharmaceuticals
NASDAQ Global Market
Aquestive Therapeutics
NASDAQ Global Market
Avadel Pharmaceuticals
NASDAQ Global Market
FAQ
What is the Vericel share price?
As of Today at 23:57 UTC, shares in Vericel are trading at $39.73. This share price information is delayed by 15 minutes.
How has the Vericel share price performed this year?
Shares in Vericel last closed at $39.73 and the price had moved by -12.59% over the past 365 days. In terms of relative price strength the Vericel share price has underperformed the S&P500 Index by -19.31% over the past year.
What are the analyst and broker recommendations for Vericel?
The overall consensus recommendation for Vericel is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Vericel dividend yield?
Vericel does not currently pay a dividend.
Does Vericel pay a dividend?
Vericel does not currently pay a dividend.
When does Vericel next pay dividends?
Vericel does not currently pay a dividend.
How do I buy Vericel shares?
To buy shares in Vericel you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Vericel?
As of the previous close price of $39.73, shares in Vericel had a market capitalisation of $1.99bn.
Where are Vericel shares listed?
Here are the trading details for Vericel:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: VCEL
What kind of share is Vericel?
Based on an overall assessment of its quality, value and momentum Vericel is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Vericel share price forecast for 2025?
The analyst consensus target price for shares in Vericel is $63.75. That is 60.46% above the last closing price of $39.73.
Analysts covering Vericel currently have a consensus Earnings Per Share (EPS) forecast of $0.33 for the next financial year.
Find out moreWhat is the trend in the Vericel share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vericel. Over the past six months, its share price has underperformed the S&P500 Index by -4.29%.
As of the last closing price of $39.73, shares in Vericel were trading -20.41% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Vericel PE Ratio?
The Vericel PE ratio based on its reported earnings over the past 12 months is 85.96. The shares last closed at $39.73.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Vericel?
Vericel's management team is headed by:
- Robert Zerbe - NEC
- Dominick Colangelo - PRE
- Joseph Mara - CFO
- Michael Halpin - COO
- Sean Flynn - VPR
- Jonathan Hopper - OTH
- Steven Gilman - IND
- Heidi Hagen - IND
- Kevin Mclaughlin - IND
- Alan Rubino - IND
- Paul Wotton - IND
- Lisa Wright - IND